SteelPeak Wealth LLC Makes New $385,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

SteelPeak Wealth LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 400 shares of the biopharmaceutical company’s stock, valued at approximately $385,000.

Several other institutional investors have also modified their holdings of REGN. River Street Advisors LLC lifted its position in Regeneron Pharmaceuticals by 7.0% in the first quarter. River Street Advisors LLC now owns 460 shares of the biopharmaceutical company’s stock worth $443,000 after buying an additional 30 shares during the last quarter. New Mexico Educational Retirement Board lifted its holdings in shares of Regeneron Pharmaceuticals by 10.7% in the 1st quarter. New Mexico Educational Retirement Board now owns 6,200 shares of the biopharmaceutical company’s stock worth $5,967,000 after acquiring an additional 600 shares during the last quarter. Burns J W & Co. Inc. NY purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $1,001,000. Hennion & Walsh Asset Management Inc. grew its holdings in Regeneron Pharmaceuticals by 22.0% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 2,365 shares of the biopharmaceutical company’s stock valued at $2,276,000 after purchasing an additional 426 shares during the last quarter. Finally, Trifecta Capital Advisors LLC raised its position in Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Trifecta Capital Advisors LLC now owns 3,298 shares of the biopharmaceutical company’s stock worth $3,174,000 after purchasing an additional 765 shares during the period. 83.31% of the stock is owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the sale, the director now owns 1,382 shares in the company, valued at $1,347,256.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Bonnie L. Bassler sold 756 shares of the firm’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,467,684. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael S. Brown sold 1,172 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,971 shares of company stock worth $61,217,654. 7.48% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. JPMorgan Chase & Co. boosted their target price on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Monday, June 17th. Evercore ISI assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Argus upped their target price on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,229.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, June 24th. Finally, Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,027.55.

Regeneron Pharmaceuticals Stock Up 0.0 %

NASDAQ:REGN opened at $1,051.03 on Monday. The company’s 50-day simple moving average is $984.27 and its 200-day simple moving average is $951.53. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $688.52 and a fifty-two week high of $1,081.17. The stock has a market capitalization of $115.81 billion, a P/E ratio of 31.05, a P/E/G ratio of 2.17 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). The business had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.